Option chain shows key data for Evaxion Biotech's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Evaxion Biotech.

Evaxion Biotech (NASDAQ:EVAX) Stock, Option Chain

Evaxion Biotech

Evaxion Biotech AS is a clinical-stage biotech company that aspires to the exploration of artificial intelligence, or AI, to develop immunotherapies with improved efficacy when compared to currently marketed products for patients with unmet medical needs. Its pipeline programs are derived from its proprietary AI platforms, PIONEER, EDEN, RAVEN, and ObsERV. The company is utilizing these AI platforms to build a drug development pipeline. Its product candidates are: EVX-01, EVX-03, and EVX-02, which are vaccine candidates being developed for the treatment of various solid cancers. In addition, the company is developing EVX-B1, EVX-B2, EVX-B3, EVX-V1, and multiple other vaccine candidates for various infectious diseases, such as cytomegalovirus, N.gonorrhoeae, bacterial pathogens, and others.

Palantir,Technologies,Japan,Logo,,Tokyo,,Japan,2024,Sep.15

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

AREB

AZTR

BCTX

EVAX

HCWB

ILMN

IVVD

KAPA

PDLB

PLTR

REBN

TNXP

UOKA

XPEV

ZONE

Why Palantir Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket

twilio shutter3

ACON

ACTG

ALUR

BTAI

CNTA

DALN

DWTX

FFBC

HYZN

LITM

MLYS

NVNI

PBBK

SEPN

STBX

TRUG

TWLO

Why Twilio Shares Are Trading Higher By Over 18%; Here Are 20 Stocks Moving Premarket

Wall Street

Long Ideas

AREN

GDYN

GEAR

VIRX

Castellum, Viracta Therapeutics And 3 Stocks To Watch Heading Into Friday (CORRECTED)

Evaxion Biotech A/S - American Depositary Share

Evaxion Biotech AS

Press Releases

Evaxion announces pricing of $10.8 million public offering

Evaxion announces closing of $10.8 million public offering

Peraso Inc. (NASDAQ: PRSO) Rides Military AI Boom as Defense Spending Surges – More Stocks Inside

Nasdaq confirms Evaxion is fully compliant, withdraws delisting determination

Evaxion extends phase 2 trial with personalized cancer vaccine EVX-01 to further enhance clinical data package

Evaxion to present at numerous upcoming conferences

Evaxion to present new phase 2 data for AI-designed personalized cancer vaccine EVX-01 at AACR Annual Meeting

Evaxion to announce business update and full year 2024 financial results on April 1, 2025

Evaxion announces business update and full year 2024 financial results

Evaxion to present at World Vaccine Congress

GSIT

PRSO

QNTM

Acurx Pharmaceuticals, Inc. - Common Stock

Acurx Pharmaceuticals

Ainos

Aprea Therapeutics

BioCardia

BioLineRx Ltd. - American Depositary Shares

BioLine Rx

BioRestorative Therapies, Inc. - Common Stock

BioRestorative Therapies

BioXcel Therapeutics, Inc. - Common Stock

BioXcel Therapeutics

Carisma Therapeutics, Inc. - Common Stock

CARISMA Therapeutics

Channel Therapeutics Corporation Common Stock

Channel Therapeutics

Dogwood Therapeutics, Inc. - Common Stock

Dogwood Therapeutics

Ernexa Therapeutics

HCW Biologics

HOOKIPA Pharma

iBio

Imunon

Immuron Limited - American Depositary Shares

Immuron

MetaVia

Minerva Neurosciences, Inc - Common Stock

Minerva Neurosciences

NextCure

Phio Pharmaceuticals Corp. - Common Stock

Phio Pharma

PharmaCyte Biotech

Rallybio

TransCode Therapeutics, Inc. - Common Stock

TransCode Therapeutics

Sensei Biotherapeutics, Inc. - Common Stock

Sensei Biotherapeutics

Synlogic

HC Wainwright & Co.

Lake Street

Ladenburg Thalmann

Oppenheimer

Comments

Evaxion Biotech

Evaxion Biotech (EVAX) Options

No option chain data available. Please try again later

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell